$FBRX
Forte Biosciences, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024127031 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.759M
YoY Change -28.34%
% of Gross Profit
Research & Development $5.720M
YoY Change -10.19%
% of Gross Profit
Depreciation & Amortization $10.00K
YoY Change
% of Gross Profit
Operating Expenses $8.629M
YoY Change -15.53%
Operating Profit -$8.629M
YoY Change -15.53%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $237.0K
YoY Change -9.2%
Pretax Income -$8.392M
YoY Change -15.74%
Income Tax
% Of Pretax Income
Net Earnings -$8.392M
YoY Change -15.7%
Net Earnings / Revenue
Basic Earnings Per Share -$4.54
Diluted Earnings Per Share -$4.54
COMMON SHARES
Basic Shares Outstanding 1.462M 36.50M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.36M
YoY Change -64.58%
Cash & Equivalents $16.40M
Short-Term Investments
Other Short-Term Assets $1.305M
YoY Change 45.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.67M
YoY Change -62.49%
LONG-TERM ASSETS
Property, Plant & Equipment $86.00K
YoY Change -12.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $192.0K
YoY Change -71.72%
Total Long-Term Assets $278.0K
YoY Change -64.22%
TOTAL ASSETS
Total Short-Term Assets $17.67M
Total Long-Term Assets $278.0K
Total Assets $17.95M
YoY Change -62.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.159M
YoY Change -3.64%
Accrued Expenses $3.421M
YoY Change 61.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.580M
YoY Change 14.84%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.580M
Total Long-Term Liabilities $0.00
Total Liabilities $8.580M
YoY Change 14.4%
SHAREHOLDERS EQUITY
Retained Earnings -$146.8M
YoY Change 30.37%
Common Stock $156.2M
YoY Change 2.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.366M
YoY Change
Total Liabilities & Shareholders Equity $17.95M
YoY Change -62.52%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$8.392M
YoY Change -15.7%
Depreciation, Depletion And Amortization $10.00K
YoY Change
Cash From Operating Activities -$8.133M
YoY Change -10.23%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.000K
YoY Change -100.01%
NET CHANGE
Cash From Operating Activities -8.133M
Cash From Investing Activities 0.000
Cash From Financing Activities -2.000K
Net Change In Cash -8.135M
YoY Change -131.59%
FREE CASH FLOW
Cash From Operating Activities -$8.133M
Capital Expenditures $0.00
Free Cash Flow -$8.133M
YoY Change -10.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001419041
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2024Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202006Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38052
dei Entity Registrant Name
EntityRegistrantName
FORTE BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1243872
dei Entity Address Address Line1
EntityAddressAddressLine1
3060 Pegasus Park Drive, Building 6
dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75247
dei City Area Code
CityAreaCode
310
dei Local Phone Number
LocalPhoneNumber
618-6994
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
FBRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1461934
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16363000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37125000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1305000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1202000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
17668000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
38327000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
86000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
109000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
192000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
544000
CY2024Q3 us-gaap Assets
Assets
17946000
CY2023Q4 us-gaap Assets
Assets
38980000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5159000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1424000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3421000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2242000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8580000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3666000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1460007
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1460007
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1453402
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1453402
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
156207000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
153829000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-146843000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-118520000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
9366000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
35314000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17946000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38980000
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5720000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6369000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
15634000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
18295000
CY2024Q3 fbrx Research And Development For Related Party
ResearchAndDevelopmentForRelatedParty
150000
fbrx Research And Development For Related Party
ResearchAndDevelopmentForRelatedParty
329000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2759000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3847000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13288000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7810000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
8629000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
10216000
us-gaap Operating Expenses
OperatingExpenses
29251000
us-gaap Operating Expenses
OperatingExpenses
26105000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8629000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10216000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29251000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26105000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
237000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
261000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
928000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
501000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-8392000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9955000
us-gaap Net Income Loss
NetIncomeLoss
-28323000
us-gaap Net Income Loss
NetIncomeLoss
-25604000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.54
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.54
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.57
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-15.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-15.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-23.97
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-23.97
CY2024Q3 fbrx Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Diluted
WeightedAverageNumberOfSharesAndPreFundedWarrantsOutstandingDiluted
1847644
CY2024Q3 fbrx Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Basic
WeightedAverageNumberOfSharesAndPreFundedWarrantsOutstandingBasic
1847644
CY2023Q3 fbrx Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Diluted
WeightedAverageNumberOfSharesAndPreFundedWarrantsOutstandingDiluted
1514509
CY2023Q3 fbrx Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Basic
WeightedAverageNumberOfSharesAndPreFundedWarrantsOutstandingBasic
1514509
fbrx Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Diluted
WeightedAverageNumberOfSharesAndPreFundedWarrantsOutstandingDiluted
1845407
fbrx Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Basic
WeightedAverageNumberOfSharesAndPreFundedWarrantsOutstandingBasic
1845407
fbrx Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Diluted
WeightedAverageNumberOfSharesAndPreFundedWarrantsOutstandingDiluted
1068019
fbrx Weighted Average Number Of Shares And Pre Funded Warrants Outstanding Basic
WeightedAverageNumberOfSharesAndPreFundedWarrantsOutstandingBasic
1068019
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-8392000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9955000
us-gaap Net Income Loss
NetIncomeLoss
-28323000
us-gaap Net Income Loss
NetIncomeLoss
-25604000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
8000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-6000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-5000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8384000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9961000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28326000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25609000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
35314000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-16000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
805000
CY2024Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-6000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7420000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
28685000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-10000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
802000
CY2024Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-5000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-12511000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
16961000
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-7000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
791000
CY2024Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
8000
CY2024Q3 fbrx Settlement Of Fractional Shares Paid In Cash Value
SettlementOfFractionalSharesPaidInCashValue
-1000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-8392000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
9366000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
38818000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
877000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6753000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
32948000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-24000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
855000
CY2023Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8896000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
24884000
CY2023Q3 fbrx Stock Issued During Period Value Issuance Of Common Stock And Warrants Under Private Investment In Public Equity Pipe Net
StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsUnderPrivateInvestmentInPublicEquityPipeNet
24728000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-24000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
9000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
772000
CY2023Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-6000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9955000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
40408000
us-gaap Net Income Loss
NetIncomeLoss
-28323000
us-gaap Net Income Loss
NetIncomeLoss
-25604000
us-gaap Depreciation
Depreciation
29000
us-gaap Depreciation
Depreciation
3000
us-gaap Share Based Compensation
ShareBasedCompensation
2398000
us-gaap Share Based Compensation
ShareBasedCompensation
2504000
fbrx Accretion Of Debt Discount On Available For Sale Securities
AccretionOfDebtDiscountOnAvailableForSaleSecurities
2000
fbrx Accretion Of Debt Discount On Available For Sale Securities
AccretionOfDebtDiscountOnAvailableForSaleSecurities
139000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-249000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
699000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3735000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4137000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1178000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
61000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20736000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19737000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
71000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
10099000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9965000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
63000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24792000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
14000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
15000
fbrx Taxes Paid Related To Net Share Settlement Of Equity Awards
TaxesPaidRelatedToNetShareSettlementOfEquityAwards
33000
fbrx Taxes Paid Related To Net Share Settlement Of Equity Awards
TaxesPaidRelatedToNetShareSettlementOfEquityAwards
48000
fbrx Settlement Of Fractional Shares Paid In Cash
SettlementOfFractionalSharesPaidInCash
1000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-20000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24759000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20762000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5085000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37125000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41100000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16363000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46185000
fbrx Unpaid Issuance Costs
UnpaidIssuanceCosts
64000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
30000
CY2024Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
reverse stock split of the issued common stock of the Company
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-146800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20700000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. Significant management estimates that affect the reported amounts of assets, liabilities and expenses include stock-based compensation expense and accruals for clinical trials and drug manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although these estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span>
CY2024Q3 fbrx Transfers Between Fair Value Hierarchy Levels
TransfersBetweenFairValueHierarchyLevels
0
CY2024Q3 fbrx Number Of Prefunded Or Common Stock Warrants Exercised
NumberOfPrefundedOrCommonStockWarrantsExercised
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
246436
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
150759
CY2024Q3 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2024Q3 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2024-01-01
CY2024Q3 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
true
CY2024Q3 fbrx Prepaid Manufacturing And Research Expenses
PrepaidManufacturingAndResearchExpenses
86000
CY2023Q4 fbrx Prepaid Manufacturing And Research Expenses
PrepaidManufacturingAndResearchExpenses
306000
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
332000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
318000
CY2024Q3 fbrx Prepaid Professional Fee
PrepaidProfessionalFee
613000
CY2023Q4 fbrx Prepaid Professional Fee
PrepaidProfessionalFee
413000
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
274000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
165000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1305000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1202000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
124000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
118000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
38000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
86000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
109000
CY2024Q3 fbrx Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
135000
CY2023Q4 fbrx Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
280000
CY2023Q4 fbrx Prepaid Professional Fees Noncurrent
PrepaidProfessionalFeesNoncurrent
211000
CY2024Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
57000
CY2023Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
53000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
192000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
544000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
105000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
276000
CY2024Q3 fbrx Accrued Compensation
AccruedCompensation
1219000
CY2023Q4 fbrx Accrued Compensation
AccruedCompensation
947000
CY2024Q3 fbrx Accrued Manufacturing And Research Expenses
AccruedManufacturingAndResearchExpenses
1432000
CY2023Q4 fbrx Accrued Manufacturing And Research Expenses
AccruedManufacturingAndResearchExpenses
1016000
CY2024Q3 fbrx Accrued Legal Settlement
AccruedLegalSettlement
650000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
15000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3421000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2242000
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9999000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
10000000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
25160000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
25164000
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
79000
us-gaap Operating Lease Expense
OperatingLeaseExpense
225000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
42000
us-gaap Operating Lease Expense
OperatingLeaseExpense
66000
CY2024Q3 us-gaap Contractual Obligation
ContractualObligation
4400000
CY2023Q3 us-gaap Loss Contingency Lawsuit Filing Date1
LossContingencyLawsuitFilingDate1
2023-08-10
CY2023Q3 us-gaap Loss Contingency Name Of Plaintiff
LossContingencyNameOfPlaintiff
Camac Fund LP
CY2023Q3 us-gaap Loss Contingency Name Of Defendant
LossContingencyNameOfDefendant
members of the Company's Board of Directors (the "Directors") and entities affiliated with certain of the Company’s investors (the “Investors”) and naming the Company as nominal defendant.
CY2023Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
25000000
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
364000
CY2024Q3 fbrx Estimated Accrued Legal Settlement
EstimatedAccruedLegalSettlement
1700000
CY2024Q3 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
364000
CY2024Q3 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
1500000
CY2023Q4 us-gaap Loss Contingency Lawsuit Filing Date1
LossContingencyLawsuitFilingDate1
2023-10-28
CY2023Q4 us-gaap Loss Contingency Name Of Plaintiff
LossContingencyNameOfPlaintiff
Forte Biosciences
CY2023Q4 us-gaap Loss Contingency Name Of Defendant
LossContingencyNameOfDefendant
Camac Fund, LP
CY2024Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
650000
CY2024Q3 fbrx Number Of Prefunded Warrants Exercised
NumberOfPrefundedWarrantsExercised
0
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
862421
CY2023Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2024-07-12
CY2024Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2024-07-12
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.25
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.76
CY2024Q3 fbrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
7.99
CY2023Q3 fbrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
20.24
fbrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
16.88
fbrx Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Of Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsOfCommonStock
21.41
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0366
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0445
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0408
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0434
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M17D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M13D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0993
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1386
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1015
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1219
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
105791
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
206.47
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M1D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
123600
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
14890
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
129.00
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
214501
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
102.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y29D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
214501
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
102.63
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y29D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
62773
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
276.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M25D
fbrx Share Based Compensation Arrangement By Share Based Payment Award Options Fair Value Of Stock Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairValueOfStockPrice
5.59
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
791000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
772000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2398000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2504000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M17D
CY2024Q3 us-gaap Professional Fees
ProfessionalFees
150000
us-gaap Professional Fees
ProfessionalFees
329000
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
0
us-gaap Professional Fees
ProfessionalFees
0
CY2024Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
28000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
57000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-127031-index-headers.html Edgar Link pending
0000950170-24-127031-index.html Edgar Link pending
0000950170-24-127031.txt Edgar Link pending
0000950170-24-127031-xbrl.zip Edgar Link pending
fbrx-20240930.htm Edgar Link pending
fbrx-20240930.xsd Edgar Link pending
fbrx-ex31_1.htm Edgar Link pending
fbrx-ex31_2.htm Edgar Link pending
fbrx-ex32_1.htm Edgar Link pending
fbrx-20240930_htm.xml Edgar Link completed
fbrx-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable